Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization epigenetic treatment for people with cancer and other serious diseases. The Company’s lead product candidate TAZVERIK (tazemetostat) is an oral selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT). AZVERIK is available to the eligible patients and their physicians in the United States through a specialty distribution network. The Company is developing tazemetostat for the treatment of a range of cancer types in multiple treatment settings. Tazemetostat is a pipeline product, which is showing clinical activity as an investigational monotherapy in multiple cancer indications.